字号·· | 护眼
华盛顿邮报

白血病疫苗通过关键试验,为抗癌药物突破之年再添成果Leukemia vaccine passes key trial, adding to breakthrough year for cancer drugs

点「原文对照」整页切到原文,或双击某段只看那段的原文。

血液涂片的光学显微镜图像,显示白血病。(南伊利诺伊大学/科学图片库)Light microscope image of blood smear indicating leukemia. (Southern Illinois University/Science Source)

据药企称,疫苗降低了某些急性髓系白血病患者的死亡风险。显微镜下的血液涂片图像显示白血病细胞。(南伊利诺伊大学/科学图片库)药企 Sellas Life Sciences 与纪念斯隆·凯特琳癌症中心周二宣布,一种首创的急性髓系白血病疫苗在 3 期临床试验中取得成功,标志着癌症疫苗在突破性的一年里又取得了一项积极成果。

The vaccine reduced risk of death for certain acute myeloid leukemia patients, according to drugmaker. Light microscope image of blood smear indicating leukemia. (Southern Illinois University/Science Source) A first of its kind vaccine for acute myeloid leukemia, a deadly blood cancer, succeeded in a Phase 3 clinical trial, drugmaker Sellas Life Sciences and Memorial Sloan Kettering Cancer Center announced Tuesday, marking another positive result in a breakthrough year for cancer vaccines .

据 Sellas 称,在一项入组 126 名患者的试验中,接受该疫苗 galinpepimut-S(GPS)治疗的患者,与接受其他白血病治疗的患者相比,死亡风险降低了 41%。Sellas 公布了该试验的初步数据。

Patients given the vaccine, galinpepimut-S (GPS), had a 41 percent reduction in risk of death compared to those given other treatments for leukemia, according to Sellas, which presented initial data from a trial of 126 patients. GPS was tested on patients who achieved a second or later complete remission for leukemia, meaning patients who were successfully treated for the disease at least twice.

GPS 在实现第二次或更多次完全缓解的白血病患者身上进行了测试,即至少成功治愈过两次疾病的患者。急性髓系白血病每年在美国影响约 2 万人,通常采用化疗治疗,但癌细胞残留常见,复发率高。

Acute myeloid leukemia, which affects around 20,000 people a year in the United States, is usually treated with chemotherapy, but remnants of the cancer often remain and recurrence is common. The results come after another cancer vaccine, intismeran , succeeded in a Phase 3 trial for treating melanoma earlier this year.

此前今年早些时候,另一种癌症疫苗 intismeran 在治疗黑色素瘤的 3 期试验中取得成功。GPS 与其有一关键区别:intismeran 是个性化 mRNA 疫苗,需要患者肿瘤样本逐例生产;而 GPS 旨在用同一种药物治疗所有患者。

GPS differs from it in a key way — while intismeran is a personalized mRNA vaccine that requires a sample from a patient’s tumor to produce on a case-by-case basis, GPS is designed to treat all patients with the same drug.

“这很可能是一种现成的疫苗,而不是每次为每位患者都要重新设计的疫苗,”大卫·谢恩伯格说,他是纪念斯隆凯特琳癌症中心实验治疗中心主席,也是GPS的研发者。(谢恩伯格还担任塞拉斯公司董事会成员,该公司从纪念斯隆凯特琳癌症中心获得GPS的授权。)塞拉斯公司表示,该公司将在未来的医学会议上公布该试验的全部数据,包括白血病无生存期和复发无生存期等次要目标的数据。

“This is potentially an off-the-shelf vaccine, not one that you would have to reengineer each time for each patient,” said David Scheinberg, chairman of the Experimental Therapeutics Center at Memorial Sloan Kettering Cancer Center and the developer of GPS. (Scheinberg also sits on the board of directors of Sellas, which licenses GPS from Memorial Sloan Kettering Cancer Center). Sellas will release full data from the trial, including data on secondary goals like leukemia-free survival and relapse-free survival, at a future medical conference, the company said.

据塞拉斯公司称,该疫苗“总体耐受性良好”,副作用最常见的是局部注射部位反应。

The vaccine was “generally well tolerated” and side effects were most commonly local injection site reactions, according to Sellas.

GPS的临床试验调查了其对急性髓系白血病患者的疗效,这些患者要么两次达到完全缓解,要么达到伴有不完全恢复的完全缓解,即癌细胞水平下降,但其他类型的血细胞尚未恢复正常水平。

The clinical trial for GPS investigated its effectiveness for acute myeloid leukemia patients who either went into complete remission twice or complete remission with incomplete recovery, when cancer cell levels drop but other types of blood cells have not returned to normal levels.

患者还必须不符合骨髓移植条件,骨髓移植是白血病的常见治疗方法。

The patients also had to be ineligible for a bone-marrow transplant, a common treatment for leukemia.

拉维·马杰蒂说,这一群体构成了白血病患者中的一小部分——但迄今为止鲜有生路。马杰蒂是斯坦福大学医学院医学教授,也是干细胞生物学与再生医学研究所主任。

Ravi Majeti, a professor of medicine and director of the Institute for Stem Cell Biology and Regenerative Medicine at Stanford University School of Medicine, said that group comprises a small subset of leukemia patients — but one that has had few lifelines until now.

“那些患者没有任何良好的治疗选择,目前的疫苗试验正是要为他们提供获益的机会,”马杰蒂说,他未参与该试验。他补充说,在试验全部数据公布之前,应谨慎评估该疫苗。

“Those patients don’t have any good therapy options, and that’s where the current vaccine trial is placed to provide a benefit,” said Majeti, who was not involved with the trial. He added that the vaccine should be evaluated with caution until full data from the trial is released.

据塞拉斯公司称,接受GPS治疗的患者中位生存期为24个月,而其他治疗为14.7个月。据美国国立卫生研究院称,急性髓系白血病的总体五年生存率约为33%。

Patients treated with GPS survived a median of 24 months compared to 14.7 months with other treatment, according to Sellas. Acute myeloid leukemia overall has a five-year survival rate of around 33 percent, according to the National Institutes of Health.

与其他癌症疫苗一样,GPS的作用是促使患者的免疫系统攻击癌细胞,而免疫系统通常无法识别这些细胞。这样,患者的身体就能“清除”化疗漏掉的少量白血病残余,降低复发风险,谢因伯格说。

Like other cancer vaccines, GPS works by prompting a patient’s immune system to attack cancer cells, which it normally fails to target. That allows a patient’s body to “mop up” the small remnants of leukemia that chemotherapy misses and reduce the risk of recurrence, Scheinberg said.

虽然黑色素瘤疫苗因特米兰使用的是更适合快速研制个性化疫苗的信使RNA新兴技术,但GPS是基于肽的。肽疫苗是一种更成熟的药物类型,通过输送蛋白质来诱导免疫系统反应。

While intismeran, the melanoma vaccine, used the burgeoning technology of messenger RNA that was more suited for quickly creating personalized vaccines, GPS is peptide-based. Peptide vaccines, a more established type of drug, deliver a protein to prompt an immune system response.

这两种疫苗今年都取得了成功的临床试验,这表明开发未来癌症疫苗有多种有前景的方法,谢因伯格说。他希望未来在其他类型的白血病和其他癌症上测试GPS。

That both vaccines had successful trials this year suggests that there are multiple promising approaches to developing future cancer vaccines, Scheinberg said. He hopes to test GPS on other types of leukemia and other cancers in the future.

“我认为,这是癌症疫苗开发一个非常有前景的时代的开始,这个时代将在未来几年不断发展,”他说。

“It’s, I think, the beginning of a very promising era of cancer vaccine development that will evolve over the next few years,” he said.

塞拉斯公司计划在2027年上半年准备向美国食品药品监督管理局提交该疫苗的审批申请,该公司表示。

Sellas plans to prepare to submit the vaccine for approval by the Food and Drug Administration in the first half of 2027, the company said.

阅读媒体原文 ↗